Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11893412 | 0.84 | ALDH1A1 (0.72) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL30881266 | 0.82 | LMNA (0.68) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL899628 | 0.82 | LMNA (0.68) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL10520781 | 0.82 | LMNA (0.68) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL1065677 | 0.82 | LMNA (0.68) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL10332625 | 0.81 | LMNA (0.67) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL7184918 | 0.81 | TSHR (0.82) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL11893919 | 0.81 | HPGD (0.59) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL11893918 | 0.81 | HPGD (0.59) | GPBAR1POLBKMT2AMEN1LMNA | |
| SCHEMBL11911203 | 0.81 | HPGD (0.59) | GPBAR1POLBKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668183-B1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2017-11-01 | — | — | EP | disclosed |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| WO-2012101261-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | 4SC DISCOVERY GMH (DE) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196861-A1 | IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION | IFNG, IL17A, IL2 | GPBAR1 1050/4885POLB 512/4885KMT2A 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.